Aptamer Group plc Fiscal Year Results

YORK, UK – Aptamer Group plc (AIM: APTA), a developer specializing in Optimer® binders for the life sciences sector, has released its full fiscal year results, highlighting strategic advances and partnerships aimed at licensing its Optimer assets. The company reported a revenue of £0.9 million for the period ending June 30, 2024, with a notable increase in commercial activity in the latter half of the financial year.

Aptamer Group has been actively restructuring, including board changes and cost reductions, to streamline the delivery of its strategic objectives. The last quarter saw the company win £1.0 million in orders, reflecting a rebuilt commercial pipeline and renewed momentum.

Key Developments

• Increased engagement with a top five pharmaceutical partner for licensing critical reagents.
• Collaboration with Unilever (LON:ULVR) to test Optimer in deodorants.
• Advancement of Optimer development for an early Alzheimer's disease lateral flow test.
• Collaboration with AstraZeneca (NASDAQ:AZN) on a fibrotic liver delivery vehicle.

Financial Highlights

• Improved cash balance: £0.9 million (up from £0.2 million last year).
• Adjusted EBITDA loss reduced: £2.8 million (down from £4.7 million).
• Administration expenses cut down to £3.2 million (from £5.0 million).
• Raised £3.5 million net proceeds from equity offerings in late 2023 and an additional £2.6 million post-period in August 2024.

Post-Period Activities

The completion of an Optimer delivery vehicle for a genetic medicines biotechnology company presents potential for future licensing. Development of Optimer binders for a new prenatal diagnostic platform continues, with ongoing contracts potentially worth £0.9 million.

CEO Arron Tolley emphasized the company's focus on asset development, commercial traction, and cost discipline, highlighting technical advancements in immunohistochemistry and gene therapy delivery that have spurred commercial interest and collaborations with top pharmaceutical companies.

The report indicates Aptamer Group is positioning itself for future growth through its strategic focus on developing and licensing its Optimer technology, supported by disciplined cost management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.